{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-292121","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.277276+00:00","generated_at":"2026-06-07T14:58:06.341602+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IN8bio reports 100% of evaluable patients in Phase 1 INB-100 trial remain in complete remission","bullets":["All 10 evaluable patients alive, progression-free, and in durable CR as of Nov 3, 2023; 6 relapse-free for over 1 year.","No dose-limiting toxicities observed; low-grade acute GVHD in 60% of patients.","Gamma-delta T cells expanded and persisted >365 days post single dose; dose response shows 48.9x greater at day 60 for DL 2 vs HSCT alone.","Two patients progression-free for over 3 years; individual follow-up ranges 4.9 to 42.7 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-292121","json":"https://secwatch.observer/filing/0001193125-23-292121.json","markdown":"https://secwatch.observer/filing/0001193125-23-292121.md","text":"https://secwatch.observer/filing/0001193125-23-292121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523292121/0001193125-23-292121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523292121/d747940d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:58:06.341602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}